RxDoctor Payments Data

Stephen Powell, MD

Ophthalmology · Morgantown, WVNPI 1982777017

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for ophthalmology clinicians in WV, where the typical reported total is $704.

$429in general payments, 2019–2025

Across 15 payments — averaging $28.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$86
  • Omeros Corporation$79
  • Carl Zeiss Meditec USA, Inc.$59
  • Rxsight Inc$53
  • Ocular Therapeutix, Inc.$43
  • Mallinckrodt Enterprises LLC$43
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$41095%
  • Gifts$195%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$429 in reported general payments places this provider in the 40th percentile of 85 ophthalmology providers in West Virginia.

See all ophthalmology providers in West Virginia

Medicare billing

Part B allowed, 2024
$104,644
Medicare patients
387
Services billed
672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost55$25,359
RestasisCyclosporine16$19,076
Latanoprost738$7,452
CombiganBrimonidine Tartrate/Timolol15$6,287
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$5,745
RocklatanNetarsudil Mesylat/Latanoprost12$3,929
Timolol Maleate325$3,594
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat99$1,967
Brimonidine Tartrate53$1,688
Prednisolone Acetate34$1,119
ErythromycinErythromycin Base48$466
Dorzolamide Hcl22$439
Ketorolac Tromethamine19$294
Ofloxacin16$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$86$50,72286 claims
Aerie Pharmaceuticals, Inc.Rocklatan$14$3,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 85 ophthalmology providers in West Virginia.

Other ophthalmology in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →